arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Genprex, Inc.

GNPX
$2.43 ▲ +0.26 (+11.98%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
11 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Genprex, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -154.0% ↗
FCF / Share $-16.42 ↘
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-16.23M
↑ +23.1% —
FCF / Share Free cash flow per share
$-16.42
↓ -283.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 41 quarters